Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ABAC Chief Calls For Better Antibiotic R&D Incentives In Europe

Executive Summary

Fresh from raising €16m in a Series A round, Albert Palomer, CEO of Spain's ABAC Therapeutics, has outlined to Scrip the company's pathogen-specific approach to antibiotic research and his fears that biotechs in Europe are being held back by flaws in the continent's 'push' incentives schemes.

Advertisement

Related Content

REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry
Alarm As Novartis Exits Antibiotics Space
Venture Funding Deals: Celularity Launches With $250m; Generation Bio Grabs $100m Series B

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100462

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel